PriceTargets.com logo

Galapagos - GLPG Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $36.50
  • Forecasted Upside: 6.23%
  • Number of Analysts: 7
  • Breakdown:
  • 2 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 1 Strong Buy Ratings
$34.36 As of 02/24/2026 05:00 PM ET
▲ +0.49 (1.45%)

This chart shows the closing price for GLPG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Galapagos Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GLPG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GLPG

Analyst Price Target is $36.50
▲ +6.23% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Galapagos in the last 3 months. The average price target is $36.50, with a high forecast of $40.00 and a low forecast of $33.00. The average price target represents a 6.23% upside from the last price of $34.36.

This chart shows the closing price for GLPG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 7 polled investment analysts is to hold stock in Galapagos. This rating changed within the last month from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
9/2/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 2 sell ratings
Ratings as of
12/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 5 sell ratings
Ratings as of
3/1/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 4 sell ratings
Ratings as of
5/30/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 5 sell ratings
Ratings as of
8/28/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 5 sell ratings
Ratings as of
11/26/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 3 sell ratings
Ratings as of
1/25/2026
  • 1 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 2 sell ratings
Ratings as of
2/24/2026

Latest Recommendations

  • 1 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/24/2026Royal Bank Of CanadaReiterated RatingSector Perform ➝ Sector Perform$33.00
2/24/2026UBS GroupReiterated RatingMarket Perform ➝ Market Perform
2/24/2026Raymond James FinancialReiterated RatingMarket Perform ➝ Market Perform
1/22/2026Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
11/26/2025Sanford C. BernsteinInitiated CoverageHold
11/7/2025Royal Bank Of CanadaBoost TargetSector Perform ➝ Sector Perform$28.00 ➝ $32.00
10/22/2025Royal Bank Of CanadaBoost TargetSector Perform ➝ Sector Perform$27.00 ➝ $28.00
10/22/2025Leerink PartnersUpgradeHold ➝ Strong-Buy
10/21/2025Leerink PartnersSet TargetMarket Perform ➝ Outperform$29.00 ➝ $40.00
10/8/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
9/27/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
8/5/2025Deutsche Bank AktiengesellschaftReiterated RatingHold ➝ Sell
2/14/2025Morgan StanleyDowngradeEqual Weight ➝ Underweight$31.00 ➝ $22.00
1/23/2025BarclaysReiterated RatingEqual Weight ➝ Underweight
1/9/2025TD CowenDowngradeStrong-Buy ➝ Strong Sell
11/20/2024Kepler Capital MarketsDowngradeHold ➝ Reduce
11/1/2024Royal Bank Of CanadaLower TargetSector Perform ➝ Sector Perform$32.00 ➝ $30.00
9/9/2024Leerink PartnersUpgradeHold
9/9/2024Leerink PartnersInitiated CoverageMarket Perform$24.00
8/2/2024Raymond James FinancialDowngradeOutperform ➝ Market Perform
4/22/2024Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$38.00 ➝ $38.00
3/28/2024Bank of AmericaReiterated RatingNeutral ➝ Underperform$41.00 ➝ $31.00
3/7/2024Morgan StanleyInitiated CoverageEqual Weight$38.00
1/2/2024Bank of AmericaBoost TargetNeutral ➝ Neutral$41.00 ➝ $44.00
8/24/2023CitigroupDowngradeBuy ➝ Neutral
8/7/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$42.00 ➝ $40.00
7/31/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$42.00
7/24/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$42.00
5/31/2023888Reiterated RatingMaintains
5/31/2023UBS GroupInitiated CoverageNeutral
5/9/2023Morgan StanleyLower Target$44.00 ➝ $42.00
5/5/2023Raymond James FinancialUpgradeMarket Perform ➝ Outperform
2/27/2023Morgan StanleyLower TargetEqual Weight$57.00 ➝ $44.00
2/27/2023Royal Bank Of CanadaLower TargetSector Perform$53.00 ➝ $43.00
1/23/2023Jefferies Financial GroupUpgradeUnderperform ➝ Hold$49.00 ➝ $47.20
12/5/2022JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral€65.00 ➝ €50.00
11/11/2022Deutsche Bank AktiengesellschaftLower Target€50.00 ➝ €40.00
11/7/2022Royal Bank Of CanadaLower TargetSector Perform$55.00 ➝ $53.00
11/7/2022Morgan StanleyLower TargetEqual Weight$63.00 ➝ $57.00
11/7/2022Raymond James FinancialDowngradeOutperform ➝ Market Perform
10/14/2022BarclaysLower TargetEqual Weight ➝ Equal Weight€60.00 ➝ €50.00
10/13/2022Morgan StanleyBoost TargetEqual Weight$61.00 ➝ $63.00
9/9/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$80.00 ➝ $61.00
8/15/2022Morgan StanleyBoost TargetOverweight$79.00 ➝ $80.00
8/8/2022Royal Bank Of CanadaLower Target$62.00 ➝ $55.00
7/25/2022Jefferies Financial GroupDowngradeHold ➝ Underperform
7/15/2022Morgan StanleyLower TargetOverweight$80.00 ➝ $79.00
5/12/2022UBS GroupBoost TargetNeutral ➝ Neutral€52.00 ➝ €70.00
5/12/2022JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral€60.00 ➝ €65.00
2/28/2022Morgan StanleyBoost TargetOverweight$77.00 ➝ $80.00
1/28/2022Bryan, Garnier & CoUpgradeSell ➝ Buy
1/27/2022CitigroupUpgradeNeutral ➝ Buy
1/6/2022Morgan StanleyLower TargetOverweight$118.00 ➝ $77.00
11/8/2021Royal Bank Of CanadaBoost TargetSector Perform$64.00 ➝ $65.00
8/27/2021UBS GroupReiterated RatingNeutral
8/19/2021BarclaysDowngradeOverweight ➝ Equal Weight
8/11/2021JPMorgan Chase & Co.Reiterated RatingNeutral
8/9/2021Royal Bank Of CanadaLower TargetSector Perform$87.00 ➝ $64.00
8/6/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$50.00
7/15/2021Raymond James FinancialSet TargetBuy$65.80
6/7/2021BarclaysReiterated RatingOverweight
5/11/2021JPMorgan Chase & Co.Reiterated RatingNeutral
5/10/2021Morgan StanleyBoost TargetOverweight$117.00 ➝ $118.00
4/20/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuy
4/14/2021BarclaysUpgradeEqual Weight ➝ Overweight
4/12/2021UBS GroupReiterated RatingNeutral
3/11/2021Morgan StanleyLower TargetOverweight$129.00 ➝ $117.00
3/2/2021BarclaysReiterated RatingEqual Weight
2/25/2021Raymond James FinancialUpgradeMarket Perform ➝ Outperform$100.00
(Data available from 2/24/2021 forward)

News Sentiment Rating

0.38 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2025
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2025
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2025
  • 2 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2025
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2025
  • 0 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2026
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2026

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Galapagos logo
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Read More

Today's Range

Now: $34.36
Low: $34.31
High: $36.24

50 Day Range

MA: $33.50
Low: $31.55
High: $34.64

52 Week Range

Now: $34.36
Low: $22.59
High: $37.78

Volume

258,395 shs

Average Volume

79,748 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Galapagos?

The following sell-side analysts have issued stock ratings on Galapagos in the last twelve months: Deutsche Bank Aktiengesellschaft, Leerink Partners, Raymond James Financial, Inc., Royal Bank Of Canada, Sanford C. Bernstein, UBS Group AG, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for GLPG.

What is the current price target for Galapagos?

0 Wall Street analysts have set twelve-month price targets for Galapagos in the last year. Their average twelve-month price target is $36.50, suggesting a possible upside of 6.2%. Leerink Partners has the highest price target set, predicting GLPG will reach $40.00 in the next twelve months. Royal Bank Of Canada has the lowest price target set, forecasting a price of $33.00 for Galapagos in the next year.
View the latest price targets for GLPG.

What is the current consensus analyst rating for Galapagos?

Galapagos currently has 2 sell ratings, 4 hold ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GLPG, but not buy more shares or sell existing shares.
View the latest ratings for GLPG.

What other companies compete with Galapagos?

Other companies that are similar to Galapagos include Arrowhead Pharmaceuticals, Axsome Therapeutics, Cytokinetics, Vaxcyte and Krystal Biotech. Learn More about companies similar to Galapagos.

How do I contact Galapagos' investor relations team?

Galapagos' physical mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company's listed phone number is (321) 534-2900 and its investor relations email address is [email protected]. The official website for Galapagos is www.glpg.com. Learn More about contacing Galapagos investor relations.